Class 4 caution in use-Onkotrone Injection 2 mg/ml concentrate for solution for infusion

Baxter Healthcare Corporation have informed the MHRA that the Patient Information Leaflet (PIL) packed in specified batches does not contain up to date information relating to the duration of contraception required for females after stopping taking this medication.

MHRA drug alert Date: 17/3/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Baxter Healthcare Corporation, Onkotrone Injection 2 mg/ml concentrate for solution for infusion, EL(26)A/14 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries regarding this communication, contact Baxter at MedInfo_UKI@baxter.com or telephone 0800 0260516

For stock control enquiries please contact Baxter at servicecs@baxter.com or telephone 0800 028 9881